Click image to view it in full size

The ribonucleic acid (RNA) therapeutics market is expected to witness remarkable clinical advancement as therapies target “undruggable” pathways. While the industry is consolidated with very few commercialized products, the functional versatility of RNA therapeutics is attracting numerous small- to mid-size companies, poised for rapid growth. The industry is witnessing encouragement for robust clinical trials in areas of metabolic diseases, respiratory diseases, neurological diseases, etc. Also, there has been growing potential for the treatment of cancer along with immunotherapy and personalized medicine, owing to the rapid increase in funding by public & private players in RNA therapeutics development programs for cancer. Technologically advanced platforms are integrated into RNA therapeutics bioprocessing to overcome stability issues, which is likely to boost the pace of RNA therapeutics production in coming years.

Co-development of RNA therapeutics by mid-size players to ramp-up their development & production pace is a major holistic change in the RNA therapeutics industry. Midsize and large companies have ramped up the production of starting materials and the final formulation of RNA therapeutics, which is likely to propel stakeholders to seek synergistic partnerships.